Raymond James Financial Inc. Acquires Shares of 727,118 Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Raymond James Financial Inc. acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 727,118 shares of the biotechnology company’s stock, valued at approximately $3,628,000.

Several other institutional investors have also modified their holdings of ALDX. SG Americas Securities LLC increased its holdings in Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 2,822 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Aldeyra Therapeutics by 89.3% in the 3rd quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 9,087 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Aldeyra Therapeutics by 253.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 10,201 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth about $62,000. Finally, U.S. Capital Wealth Advisors LLC purchased a new stake in Aldeyra Therapeutics during the fourth quarter worth approximately $69,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Stock Down 0.6 %

Shares of ALDX opened at $6.26 on Friday. The firm has a fifty day moving average price of $6.06 and a 200 day moving average price of $5.52. Aldeyra Therapeutics, Inc has a 1-year low of $3.10 and a 1-year high of $7.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). Research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Monday, March 3rd.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.